XTX Topco Ltd Buys Shares of 14,086 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

XTX Topco Ltd purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,086 shares of the company’s stock, valued at approximately $74,000.

A number of other large investors also recently modified their holdings of the company. Nwam LLC acquired a new stake in Corvus Pharmaceuticals in the third quarter valued at $53,000. Avity Investment Management Inc. increased its holdings in Corvus Pharmaceuticals by 138.2% in the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock worth $146,000 after purchasing an additional 16,000 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in Corvus Pharmaceuticals in the third quarter valued at approximately $89,000. Towerview LLC boosted its holdings in shares of Corvus Pharmaceuticals by 4.6% during the 2nd quarter. Towerview LLC now owns 400,000 shares of the company’s stock worth $728,000 after buying an additional 17,500 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Corvus Pharmaceuticals during the 2nd quarter worth approximately $44,000. 46.64% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Trading Down 2.0 %

CRVS opened at $4.99 on Friday. The company has a market cap of $320.64 million, a price-to-earnings ratio of -5.37 and a beta of 1.05. The company’s fifty day moving average price is $8.12 and its two-hundred day moving average price is $5.09. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $10.00.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CRVS shares. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. Oppenheimer increased their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH increased their price target on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.83.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.